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In recent years the number of molecular genetic tests 
on offer and the demand for these tests has burgeoned. 
These tests are a major area of development in an 
effort to reap tangible medical benefits from the 
significant resources that have been invested in basic 
biomedical research as part of the Human Genome Project. Tests are 
now not only offered for diagnosis, carrier, presymptomatic, prenatal 
and pre-implantation testing, but also for pharmacogenetics, disease 
susceptibility, nutrigenetics and genetic relatedness. These tests have 
traditionally only been available through healthcare providers (such 
as clinicians and genetic counsellors) who would order the applicable 
test from a laboratory, collect and send the samples, interpret the test 
results and provide appropriate pre- and post-test counselling.  
What is direct-to-consumer genetic 
testing? 
Direct-to-consumer (DTC) genetic testing differs from traditional genetic 
testing in that the consumer or client can order tests and receive results 
without a healthcare provider being involved. DTC tests are usually 
marketed via the internet, television or print media. Typically, the sample 
collection kit is mailed directly to the consumer and the test usually 
involves collection of a sample for DNA analysis from swabbing the 
inside of the cheek or, in some cases, a blood sample following a visit to a 
health clinic. The sample is mailed back to the laboratory and consumers 
are notified of their results by mail, telephone, or via the internet. Service 
providers offering these tests are based locally and overseas. 
The vast majority of DTC genetic testing companies either do not 
provide genetic counselling services, or provide inadequate counselling. 
As a result, the significance of findings is open to misinterpretation 
by consumers. In the South African (SA) context, no information is 
available regarding the extent of uptake of DTC genetic testing. However, 
anecdotally there are numerous instances where members of the public 
(some distraught) have approached independent clinical geneticists and 
genetic counsellors to explain the meaning and implications of their 
results. It is anticipated that the number of consumers in SA accessing 
DTC genetic tests will rise as a result of increased awareness and an 
assumed benefit of these tests on the part of the lay public. There are 
many types of genetic tests, including those that aim to show how an 
individual might respond to a particular diet or athletic performance. 
This article, however, focuses on those tests for health-related traits. 
Genetic testing for complex 
multifactorial disorders is premature
Genetic tests offered for health-related traits can be broadly divided into 
two main classes: tests for monogenic and for complex multifactorial 
disorders. Monogenic disorders are more straightforward in terms of 
testing because the genetic defect (pathogenic mutation) in a single 
gene is the direct cause of the disorder. These disorders, referred to as 
Mendelian, comprise different modes of inheritance including autosomal 
dominant (e.g. Huntington’s disease and some forms of hereditary 
nonpolyposis colorectal cancer), autosomal recessive (e.g. cystic fibrosis 
and galactosaemia) and X-linked disorders (e.g. Duchenne muscular 
dystrophy and haemophilia). For these conditions, there is a clear 
relationship between cause and effect, i.e. if a mutation is shown to be 
present, it is likely that the individual will develop the disorder. There is 
a strong case for genetic testing when these types of disorder are present 
in a family, provided that appropriate genetic counselling is available. 
In fact, the European Academies Science Advisory Council (EASAC) 
recommends that monogenic disorders should be excluded from the 
services offered by DTC genetic testing companies unless accompanied 
by appropriate medical supervision and genetic counselling.[1]
In contrast, the majority of human disorders with a heritable 
component are of a complex and multifactorial nature. In these disorders, 
genetic variation in many genes as well as environmental risk factors, 
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including nutrition and lifestyle choices, increase the susceptibility for 
developing the condition. This means that no single genetic variant, 
or even a small number of variants, can be used to accurately predict 
risk. Despite this level of complexity, many DTC companies advocate 
the use of genetic tests for predicting susceptibility to develop complex 
disorders such as hypertension, Alzheimer’s disease, prostate cancer and 
cardiovascular diseases. We caution that at the present time, genetic tests 
for these conditions are premature and are not supported by rigorous 
scientific evidence. In addition, and very importantly, many of them 
have not been studied in different (e.g. African) populations where they 
potentially might have a different genetic aetiology.
Sequencing of the human genome has yielded important information 
including the number of human genes, the complexity of the genome 
and the sequence similarity to other species. However, it is still not 
understood how the thousands of proteins encoded by these genes 
interact in every cell and work together to ensure proper functioning 
of that cell. Even less is understood regarding the mechanisms that go 
awry and which might lead to disease.[2] If potential environmental 
contributions are added into the equation, the picture becomes even 
more complex and the exact genetic role players in unravelling the 
disease process become difficult to pin-point.
In type 2 diabetes mellitus (T2DM), which is projected to double 
in prevalence by 2030 in low- and medium-income countries, several 
genes are involved in the way insulin is produced and used by the 
body. Interaction of the genes involved in the T2DM pathway, with 
various dietary and lifestyle factors, work together to influence 
the development of the condition, as illustrated in Fig. 1. Also, 
different sequence variants could result in the lowering, increasing 
or complete lack of certain gene products, which could influence 
the severity of the condition as well as the age at which the disease 
manifests. Thus, if a variant in a gene – such as the sulfonylurea 
receptor gene (SUR1) – is offered as a genetic test, several factors 
need to be understood, including: (i) how it was determined that this 
particular variant is predictive of T2DM; (ii) its overall contribution 
relative to other potential variants in the hundreds of genes involved 
in insulin metabolism; and (iii) how these variants interact with 
the environment to increase or decrease. Similarly, an individual’s 
response to anti-diabetic drugs cannot be accurately predicted based 
on variants in a single gene, but requires knowledge of the role of 
variants in several genes and a thorough understanding of gene-gene 
and gene-environment interactions.  
Both clinicians, and the general public who lack the relevant genetic 
knowledge, could be misled into thinking that genetic testing can 
be done for any inherited disorder or any disease with a heritable 
component. One company in SA offers genetic tests for predisposition 
to various conditions including obesity, heart attack, and even offers 
a ‘well-being’ genetic test! Many of the tests are based on preliminary 
research studies with small sample sizes, borderline significance of 
association and small effects on increased risk for developing disease. 
This does not constitute sufficient scientific evidence for use in a 
clinical setting. Therefore, many of the claims that are made by service 
providers are not justified, as there are currently no scientifically 
validated diagnostic or predictive genetic tests for complex conditions. 
Furthermore, it is unlikely that there will be in the immediate future.[3,4] 
Medical and ethical concerns
We are aware that DTC genetic testing is here to stay and that it does 
have some advantages. Some of these benefits include the accessibility 
of tests to the public, increased awareness of genetic disorders and 
enabling consumers to play a proactive role in their healthcare. DTC 
genetic testing companies can empower individuals by making available/ 
accessible tests that are difficult to access through the healthcare system. 
In addition, they offer interesting opportunities for ‘genetic hobbyists’ to 
learn about their ancestral origins and recreational genetics outcomes, 
such as whether one has the genetic variations that make Brussels sprouts 
taste bitter or that determine whether one has wet or dry ear-wax. 
However, there are major concerns about tests that claim to accurately 
predict susceptibility to complex diseases owing to misinterpretation 
of results, unrealistic expectations, anxiety and inappropriate medical 
decisions.[1] Parkinson’s disease (PD), a debilitating, progressive neuro-
degenerative disorder, currently without a cure, illustrates some of these 
concerns. The pathogenic mutation, G2019S, found in the leucine-rich 
repeat kinase 2 (LRRK2) gene, is present in about 1 - 2% of sporadic 
PD cases (these are families in which there is only a single affected 
individual). As a result of founder effects (where a mutation occurs 
at a relatively high frequency in a specific population due to its small 
number of ancestors) the frequency of G2019S in the PD population of 
Ashkenazi Jewish and North African Arabic origin is approximately 1 in 
every 5 patients[5] and 1 in every 3 patients,[6] respectively. Due to the high 
frequency of G2019S in these two patient populations, and its virtual 
absence in healthy individuals and those with other neurodegenerative 
disorders, it is now offered to the public as a genetic test for PD. 
In some cases, this may be the only mutation that a particular service 
provider will screen for in their PD screening test. A negative test for 
the G2019S mutation does not necessarily mean that the individual 
will never develop PD, as they may still harbour any one of the many 
other PD-causing mutations or they could develop the disease as a 
result of environmental risk factors, many of which are still unknown. 
Conversely, individuals who test positive for the G2019S mutation may 
never develop PD, as evidenced by some G2019S-positive individuals 
who live to their seventies and never develop neurological signs.[7]
There are many ethical issues to consider when providing genetic 
tests for disorders like PD for which there are currently no preventive 
measures or a cure.[8] In a symptomatic individual, this gene test would 
not help to improve the efficacy of treatment, patient care or prognosis 
(although this may change as the function(s) of the gene(s) involved is 
better understood, and targeted treatments are developed). Mutation 
carriers may consider prenatal or even pre-implantation genetic testing 
to avoid transmitting the mutation to their offspring. The selective 
termination of a fetus that may develop an adult-onset disorder is itself 
a subject of considerable ethical debate. Moreover, the implications of a 
positive test result for relatives, who themselves have not taken the test, 
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Fig. 1. A complex disorder such as T2DM develops as a result of genetic 
variation in a number of different genes in combination with various dietary, 
lifestyle and other currently unknown factors. *More information on the genes 
involved in T2DM can be found at the Kegg pathway database (http://www.
genome.jp/kegg-bin/show_pathway?hsa04930).
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are in fact ‘indirectly’ tested when a mutation is found. In the case of 
a dominant condition, if the test is positive it will reveal that one of 
the parents is an obligate mutation carrier and also implies that the 
siblings have a 50% chance of carrying the mutation. This ‘unsolicited’ 
information may be resented by some family members as they might 
not have considered the disorder to be hereditary and had not given 
consent to receiving such information. Consumers may also experience 
an invasion of their privacy if the testing companies use their genetic data 
in an unauthorised manner e.g. selling the data to a third party such as 
insurance companies or potential employers who may, based on these 
findings, discriminate against them. According to the Association for 
Savings and Investments SA (ASISA) guideline, insurance companies 
have rights to access the results of genetic tests performed prior to 
application for cover. Consumers should be aware of this before they 
request DTC genetic tests as it may influence their risk profile. It is 
therefore essential that the consumer receive appropriate pre- and post-
test genetic counselling and that they carefully consider the ethical issues. 
Counselling guidelines have been developed for presymptomatic genetic 
testing to ensure patient choice and safety and could be adapted for 
other scenarios.[9] Further research is needed on appropriate counselling 
guidelines and defining the boundaries of this profession as examination 
of the genetic counselling services offered by some DTC genetic testing 
service providers revealed several points of concern.[10]
Another contentious issue with DTC genetic testing is ‘surreptitious 
genetic testing’, which is the collection of a biological specimen 
for DNA extraction and the disclosure of the genetic information 
without obtaining consent from the person tested.[11] For some DTC 
testing companies, the request for specimens such as a blood sample 
or a cheek swab may prevent surreptitious sample collection; but 
other companies are willing to analyse DNA from items such as 
strands of hair, bubble gum or cigarette butts. Such testing could have 
medical and legal implications. This includes inappropriate treatment 
and initiation of parentage disputes and lawsuits, notwithstanding 
the potential quality control concerns such as chain of custody, and 
questionable laboratory practice. 
Absence of regulation in SA
Despite the numerous concerns associated with DTC genetic testing, 
in SA, and in Africa as a whole, there is a lack of guidelines and 
regulations governing these tests. In Europe and North America, various 
organisations have developed guidelines and recommendations for their 
governments and policy makers. In Europe, the EASAC has produced 
a document in which they advise against DTC genetic testing as they 
state that it has little clinical value at present and has the potential to be 
harmful.[12] Notably in Germany, the Genetic Diagnostics Act requires 
involvement of a physician in all forms of genetic testing, thereby 
effectively prohibiting DTC genetic testing. The UK Human Genetics 
Commission has provided a list of principles to ensure the provision of 
a high-quality DTC genetic testing service that meets the expectations 
of the consumer while safeguarding their interests.[13] The American 
Society for Human Genetics has published a statement which calls for 
education of healthcare providers regarding the potential benefits and 
limitations of these tests as well as the certification of all DTC genetic 
testing laboratories.[14] Also, the American College of Medical Genetics 
has issued a list of minimum requirements for a DTC genetic testing 
protocol that includes the provision of the scientific evidence on which 
the test is based in a readily understandable format.[15]  In 2008, the US 
government passed the Genetic Information Non-discrimination Act 
(GINA), protecting their citizens against discrimination based on their 
genetic information when it comes to health insurance and employment.
It is apparent that, since service providers are often based in different 
geographic locations to the clients they serve, DTC genetic testing 
will require guidelines from various international professional bodies, 
universally applicable regulations and mutual agreement on a widely 
accepted ‘code of practice’.[16] 
Recommendations for SA
We recommend that the SA National Department of Health establish 
an expert monitoring body to comprehensively and systematically 
evaluate all genetic tests provided by DTC genetic testing companies in 
SA. The evaluation must include the following key issues:
1. All genetic testing must be based on rigorous peer-reviewed scientific 
evidence and quality assurance should comprise 3 main parameters:[17]
• analytical validity (a test’s accuracy in detecting a particular genetic 
variant when present and not detecting the variant when absent)
• clinical validity (the test’s ability to distinguish between those who 
have/will develop a disorder/condition and those who will not)
• clinical utility (the likelihood of the test to significantly improve 
patient outcomes). 
2. Service providers must be transparent in their dealings with their 
clients and must provide all relevant scientific information on the 
accuracy and usefulness of the tests they offer.
3. Advertising for genetic tests must not be exploitative and must not 
overstate the benefits of the test.
4. A genetic counsellor, clinical geneticist or a clinician must be consulted 
before the genetic test is performed, to determine if the test is 
appropriate and valid, and afterwards to assist with interpretation of 
the results. A list of some SA genetic counsellors is available online.[18]
5. SA legislation must be reviewed and amended to prevent stigma-
tisation and discrimination on the basis of genetic testing by insurance 
companies and/or potential employers.
These measures are necessary to ensure that consumers in SA and 
their healthcare providers are protected from the potential harms and 
possible exploitation associated with this industry, and that their decision 
whether or not to be tested is based on a well-informed choice.
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